Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To determine whether cognitive impairment in Parkinson disease (PD) and Alzheimer disease (AD) derives from the same network pathology.
Methods: We analyzed 18F-fluorodeoxyglucose PET scans from 40 patients with AD and 40 age-matched healthy controls from the Alzheimer’s Disease Neuroimaging Initiative and scanned an additional 10 patients with AD and 10 healthy controls at The Feinstein Institute for Medical Research to derive an AD-related metabolic pattern (ADRP) analogous to our previously established PD cognition-related pattern (PDCP) and PD motor-related pattern (PDRP). We computed individual subject expression values for ADRP and PDCP in 89 patients with PD and correlated summary scores for cognitive functioning with network expression. We also evaluated changes in ADRP and PDCP expression in a separate group of 15 patients with PD scanned serially over a 4-year period.
Results: Analysis revealed a significant AD-related metabolic topography characterized by covarying metabolic reductions in the hippocampus, parahippocampal gyrus, and parietal and temporal association regions. Expression of ADRP, but not PDCP, was elevated in both AD groups and correlated with worse cognitive summary scores. Patients with PD showed slight ADRP expression, due to topographic overlap with the network underlying PD motor-related pattern degeneration, but only their PDCP expression values increased as cognitive function and executive performance declined. Longitudinal data in PD disclosed an analogous dissociation of network expression.
Conclusions: Cognitive dysfunction in PD is associated with a specific brain network that is largely spatially and functionally distinct from that seen in relation to AD.
GLOSSARY
- AD=
- Alzheimer disease;
- ADNI=
- Alzheimer’s Disease Neuroimaging Initiative;
- ADRP=
- Alzheimer disease–related pattern;
- ANOVA=
- analysis of variance;
- FDG=
- 18F-fluorodeoxyglucose;
- FIMR=
- Feinstein Institute for Medical Research;
- MCI=
- mild cognitive impairment;
- MCI(−)=
- cognitively intact;
- MCI(m)=
- mild cognitive impairment involving multiple cognitive domains;
- MCI(s)=
- mild cognitive impairment involving a single cognitive domain;
- MMSE=
- Mini-Mental State Examination;
- PD=
- Parkinson disease;
- PDCP=
- Parkinson disease cognition-related pattern;
- PDD=
- Parkinson disease dementia;
- PDRP=
- Parkinson disease motor-related pattern;
- RMANOVA=
- repeated-measures analysis of variance
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf. (also available as supplemental material).
Supplemental data at Neurology.org
- Received March 18, 2016.
- Accepted in final form July 18, 2016.
- © 2016 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David Beversdorf and Dr. Ryan Townley
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Using AD biomarker research results for clinical careA survey of ADNI investigatorsMelanie B. Shulman, Kristin Harkins, Robert C. Green et al.Neurology, August 21, 2013 -
Article
Association of blood-based transcriptional risk scores with biomarkers for Alzheimer diseaseYoung Ho Park, Angela Hodges, Andrew Simmons et al.Neurology: Genetics, September 30, 2020 -
Article
Plasma tau in Alzheimer diseaseNiklas Mattsson, Henrik Zetterberg, Shorena Janelidze et al.Neurology, September 30, 2016 -
Article
Determining clinically meaningful decline in preclinical Alzheimer diseasePhilip S. Insel, Michael Weiner, R. Scott Mackin et al.Neurology, July 09, 2019